NAMANKERAN 2

Manufacturer: Naman Pharma Drugs

Strength: 2 Mg

Details: Melphalan Tablets 2mg

The single most effective drug in treating Multiple Myeloma. Proven disease-free and an overall survival advantage in Multiple Myeloma patients. Namankeran crosslink DNA strands and prevent cells from replicating and is indicated for:

Orally:

• Palliative treatment of Multiple Myeloma;
• Palliation of Non-resectable Epithelial Carcinoma of the Ovary

Intravenous:

• As a high-dose Conditioning treatment prior to Hematopoietic progenitor (Stem)
• Cell Transplantation in patients with Multiple Myeloma.
• Palliative treatment of patients with Multiple Myeloma for whom oral therapy is not appropriate.

Dosage and Administration:

Multiple Myeloma: The usual oral dose is 6 mg daily x 2-3 weeks; 4 week break then 2 mg/day maintenance.

Epithelial Ovarian Cancer: One commonly employed regimen for the treatment of Ovarian

Carcinoma has been to administer Namankeran at a dose of 0.2 mg/kg daily for 5 days as a single course.

Courses are repeated every 4 to 5 weeks depending upon hematologic tolerance.

For Conditioning Treatment:

• The recommended dose of Namankeran is 100mg/m/day administered over 30 minutes by intravenous
• Infusion for 2 consecutive days (Day -3 and Day -2) prior to Autologous Stem Cell Transplantation
• (ASCT, Day 0). For patients who weigh more than 130% of their ideal body weight, body surface
• Area should be calculated based on adjusted ideal body weight.

For Palliative Treatment:

• The recommended dose of Namankeran is (0.4 mg/kg
• Bodyweight) 16 mg/m administered as a single intravenous infusion over 15-20 minutes at 2-week
• intervals for 4 doses, then, after adequate recovery from toxicity, at 4-week intervals. Dosage reduction of up to 50% should be considered in patients with renal insufficiency (BUN ≥30 mg/dL).